Orlance
Private Company
Funding information not available
Overview
Orlance is advancing the MACH-1 platform, a needle-free gene gun technology that delivers powdered DNA or RNA vaccines directly into the epidermis, aiming to reduce doses by up to 90% and eliminate cold chain requirements. The company has secured significant non-dilutive funding, primarily from NIH SBIR grants totaling over $16.8M, to progress its pipeline toward Phase 1 trials. With a lead universal flu vaccine at the pre-IND stage, Orlance is preparing for a $12M Series A round in 2026 and is actively seeking development partners to expand its portfolio of vaccine and immunotherapy assets.
Technology Platform
MACH-1 needle-free epidermal delivery platform using pressurized gas to deliver powdered DNA/RNA vaccines into the skin, enabling dose-sparing, thermostable vaccines.
Opportunities
Risk Factors
Competitive Landscape
Orlance competes with other needle-free delivery technologies such as jet injectors (e.g., PharmaJet), microneedle patches (e.g., Vaxxas, Micron Biomedical), and other epidermal delivery systems. Its key differentiators are the combination of powdered nucleic acid formulation, precise epidermal targeting for dose-sparing, and the elimination of cold chain, positioning it for use in resource-limited settings.